5 active not recruiting. 5 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin - Epidermolysis Bullosa Dystrophica, Recessive | Phase 1 / Phase 2 | Active not recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 3 | 2020-01-10 | 2026-02-12 |
| Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita alemtuzumab, Fludarabine, Cyclosporins - Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome | Phase 2 | Active not recruiting | Boston Children's Hospital | 40 | 2012-07-01 | 2026-03-27 |
Anemia, Aplastic (1) · Anetoderma (1) · Bone Marrow Failure Disorders (1) · Dyskeratosis Congenita (1) · Epidermolysis Bullosa Dystrophica (1) · Epidermolysis Bullosa Simplex (1) · Hoyeraal Hreidarsson syndrome (1) · Netherton Syndrome (1) · Retinitis Pigmentosa (1) · Revesz Debuse syndrome (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Congenital Abnormalities (4) · Skin Diseases, Genetic (4) · Connective Tissue Diseases (2) · Epidermolysis Bullosa (2) · Skin Diseases, Vesiculobullous (2) · Abnormalities, Multiple (1) · Anemia (1) · Bone Marrow Diseases (1) · Collagen Diseases (1) · Congenital Bone Marrow Failure Syndromes (1)
Alemtuzumab (1) · Cyclosporine (1) · Cyclosporins (1) · Mycophenolic Acid (1) · Tacrolimus (1) · diacerein (1) · fludarabine (1) · fludarabine phosphate (1)
Boston Children's Hospital (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Quoin Pharmaceuticals (1) · Rubens Camargo Siqueira (1) · TWi Biotechnology, Inc. (1)
United States (3) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · France (1) · Greece (1) · India (1) · Ireland (1) · Israel (1) · Italy (1) · Malaysia (1) · Norway (1) · Philippines (1)
Rubens C Siqueira, MD,PhD (1) · Suneet Agarwal, MD, PHD (1) · Tony Andrasfay (1)
2016 (1)